Patent classifications
C07C227/26
PROCESS FOR MAKING MIXTURES OF CHELATING AGENTS
Process for making a chelating agent according to the general formula (I), R.sup.1CH(COOX.sup.1)N(CH2COOX.sup.1).sub.2 wherein R.sup.1 is selected from hydrogen, C.sub.1-C.sub.4-alkyl, phenyl, benzyl, CH.sub.2OH, and CH.sub.2CH.sub.2COOX.sup.1, X.sup.1 is (M.sub.H.sub.1-), M being selected from alkali metal, x is in the range of from 0.6 to 1, said process comprising the following steps: (a) providing a solid, a slurry or a solution of a compound according to general formula (II a) R.sup.1CH(COOX.sup.2)N(CH.sub.2CN).sub.2 wherein X.sup.2 is (M.sub.yH.sub.1-y), M being selected from alkali metal, y is in the range of from zero to 1, (b) contacting said solid or slurry or solution with an aqueous solution of alkali metal hydroxide, wherein the molar ratio of alkali metal ions to nitrile groups is in the range of from 0.6:1 to 0.95:1, (c) reacting said compound according to general formula (II a) with said alkali metal hydroxide.
Solutions of trialkali metal salts of MGDA with an excess of L-enantiomer, their manufacture and use
Aqueous solution containing in the range of from 60.5 to 75% by weight of a mixture of trialkalimetal salts of the L-and D-enantiomers of methyl glycine diacetic acid (MGDA), said mixture containing predominantly the respective L-isomer with an enantiomeric excess (ee) in the range of from 3 to 97%, wherein said trialkali metal salts have the general formula (I) [CH.sub.3CH(COO)N(CH.sub.2COO).sub.2]K.sub.3xNa.sub.x (I) wherein x is in the range of from zero to 2.9.
Solutions of trialkali metal salts of MGDA with an excess of L-enantiomer, their manufacture and use
Aqueous solution containing in the range of from 60.5 to 75% by weight of a mixture of trialkalimetal salts of the L-and D-enantiomers of methyl glycine diacetic acid (MGDA), said mixture containing predominantly the respective L-isomer with an enantiomeric excess (ee) in the range of from 3 to 97%, wherein said trialkali metal salts have the general formula (I) [CH.sub.3CH(COO)N(CH.sub.2COO).sub.2]K.sub.3xNa.sub.x (I) wherein x is in the range of from zero to 2.9.
Solutions of trialkali metal salts of MGDA with an excess of L-enantiomer, their manufacture and use
Aqueous solution containing in the range of from 60.5 to 75% by weight of a mixture of trialkalimetal salts of the L-and D-enantiomers of methyl glycine diacetic acid (MGDA), said mixture containing predominantly the respective L-isomer with an enantiomeric excess (ee) in the range of from 3 to 97%, wherein said trialkali metal salts have the general formula (I) [CH.sub.3CH(COO)N(CH.sub.2COO).sub.2]K.sub.3xNa.sub.x (I) wherein x is in the range of from zero to 2.9.
CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS
Cure accelerators for anaerobic curable compositions, such as adhesives and sealants, are provided, and which are defined with reference to the compounds shown in structure I
##STR00001##
where A is CH.sub.2 or benzyl, R is C.sub.1-10 alkyl, R is H or C.sub.1-10 alkyl, or R and R taken together may form a four to seven membered ring fused to the benzene ring, R is optional, but when R is present, R is halogen, alkyl, alkenyl, cycloalkyl, hydroxyalkyl, hydroxyalkenyl, alkoxy, amino, alkylene- or alkenylene-ether, alkylene (meth)acrylate, carbonyl, carboxyl, nitroso, sulfonate, hydroxyl or haloalkyl, and EWG is as shown, an electron withdrawing group, such as nitro, nitrile, carboxylate or trihaloalkyl.
CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS
Cure accelerators for anaerobic curable compositions, such as adhesives and sealants, are provided, and which are defined with reference to the compounds shown in structure I
##STR00001##
where A is CH.sub.2 or benzyl, R is C.sub.1-10 alkyl, R is H or C.sub.1-10 alkyl, or R and R taken together may form a four to seven membered ring fused to the benzene ring, R is optional, but when R is present, R is halogen, alkyl, alkenyl, cycloalkyl, hydroxyalkyl, hydroxyalkenyl, alkoxy, amino, alkylene- or alkenylene-ether, alkylene (meth)acrylate, carbonyl, carboxyl, nitroso, sulfonate, hydroxyl or haloalkyl, and EWG is as shown, an electron withdrawing group, such as nitro, nitrile, carboxylate or trihaloalkyl.
Synthesis of nirogacestat
The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (nirogacestat).
Synthesis of nirogacestat
The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (nirogacestat).
Synthesis of nirogacestat
The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (nirogacestat).
Synthesis of nirogacestat
The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (nirogacestat).